{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:54:38Z","timestamp":1787500478488,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical models. Elafibranor is one of the drugs currently in late stage development which had mixed results for phase 2\/interim phase 3 trials. In the current study we investigated the response of elafibranor in APOE*3Leiden.CETP mice, a translational animal model that displays histopathological characteristics of NASH in the context of obesity, insulin resistance and hyperlipidemia. To induce NASH, mice were fed a high fat and cholesterol (HFC) diet for 15\u00a0weeks (HFC reference group) or 25\u00a0weeks (HFC control group) or the HFC diet supplemented with elafibranor (15\u00a0mg\/kg\/d) from week 15\u201325 (elafibranor group). The effects on plasma parameters and NASH histopathology were assessed and hepatic transcriptome analysis was used to investigate the underlying pathways affected by elafibranor. Elafibranor treatment significantly reduced steatosis and hepatic inflammation and precluded the progression of fibrosis. The underlying disease pathways of the model were compared with those of NASH patients and illustrated substantial similarity with molecular pathways involved, with 87% recapitulation of human pathways in mice. We compared the response of elafibranor in the mice to the response in human patients and discuss potential pitfalls when translating preclinical results of novel NASH therapeutics to human patients. When taking into account that due to species differences the response to some targets, like PPAR-\u03b1, may be overrepresented in animal models, we conclude that elafibranor may be particularly useful to reduce hepatic inflammation and could be a pharmacologically useful agent for human NASH, but probably in combination with other agents.<\/jats:p>","DOI":"10.1038\/s41598-021-83974-8","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T06:02:36Z","timestamp":1614751356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men"],"prefix":"10.1038","volume":"11","author":[{"given":"Anita M.","family":"van den Hoek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Verschuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martien P. M.","family":"Caspers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Worms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin L.","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M. G.","family":"Princen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"83974_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-020-00540-y","author":"CL Horn","year":"2020","unstructured":"Horn, C. L., Ta, A. & Gunn, N. T. Current and emerging treatments for non-alcoholic steatohepatitis. Curr. Hepatol. Rep. https:\/\/doi.org\/10.1007\/s11901-020-00540-y (2020).","journal-title":"Curr. Hepatol. Rep."},{"key":"83974_CR2","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/nutd.2014.30","volume":"4","author":"M Lai","year":"2014","unstructured":"Lai, M., Chandrasekera, P. C. & Barnard, N. D. You are what you eat, or are you? The challenges of translating high-fat-fed rodents to human obesity and diabetes. Nutr Diabetes 4, e135. https:\/\/doi.org\/10.1038\/nutd.2014.30 (2014).","journal-title":"Nutr Diabetes"},{"key":"83974_CR3","doi-asserted-by":"publisher","unstructured":"Teufel, A. et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology 151, 513\u2013525. https:\/\/doi.org\/10.1053\/j.gastro.2016.05.051 (2016).","DOI":"10.1053\/j.gastro.2016.05.051"},{"key":"83974_CR4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.046","author":"V Ratziu","year":"2020","unstructured":"Ratziu, V. & Friedman, S. L. Why do so many NASH trials fail?. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2020.05.046 (2020).","journal-title":"Gastroenterology"},{"key":"83974_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/hep.26461","volume":"58","author":"B Staels","year":"2013","unstructured":"Staels, B. et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology 58, 1941\u20131952. https:\/\/doi.org\/10.1002\/hep.26461 (2013).","journal-title":"Hepatology"},{"key":"83974_CR6","doi-asserted-by":"publisher","unstructured":"Fougerat, A., Montagner, A., Loiseau, N., Guillou, H. & Wahli, W. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells 9, https:\/\/doi.org\/10.3390\/cells9071638 (2020).","DOI":"10.3390\/cells9071638"},{"key":"83974_CR7","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. The role of PPAR-delta in Metabolism, inflammation, and cancer: many characters of a critical transcription factor. Int J Mol Sci 19, https:\/\/doi.org\/10.3390\/ijms19113339 (2018).","DOI":"10.3390\/ijms19113339"},{"key":"83974_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne, N. et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev 39, 760\u2013802. https:\/\/doi.org\/10.1210\/er.2018-00064 (2018).","journal-title":"Endocr Rev"},{"key":"83974_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.4254\/wjh.v7.i8.1012","volume":"7","author":"V Souza-Mello","year":"2015","unstructured":"Souza-Mello, V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol 7, 1012\u20131019. https:\/\/doi.org\/10.4254\/wjh.v7.i8.1012 (2015).","journal-title":"World J Hepatol"},{"key":"83974_CR10","doi-asserted-by":"publisher","unstructured":"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147\u20131159. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.038 (2016).","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"83974_CR11","unstructured":"GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis. https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/38e085e1-66f5-4251-8abe-648d0e7b9ed1; Press release (2020)."},{"key":"83974_CR12","unstructured":"Genfit. Elafibranor in NASH, https:\/\/www.genfit.com\/pipeline\/elafibranor\/ (2020)."},{"key":"83974_CR13","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1161\/ATVBAHA.107.142570","volume":"27","author":"S Zadelaar","year":"2007","unstructured":"Zadelaar, S. et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27, 1706\u20131721. https:\/\/doi.org\/10.1161\/ATVBAHA.107.142570 (2007).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"83974_CR14","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1161\/01.ATV.0000243925.65265.3c","volume":"26","author":"M Westerterp","year":"2006","unstructured":"Westerterp, M. et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26, 2552\u20132559. https:\/\/doi.org\/10.1161\/01.ATV.0000243925.65265.3c (2006).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"83974_CR15","doi-asserted-by":"publisher","unstructured":"van den Hoek, A. M. et al. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes, obesity & metabolism 16, 537\u2013544, https:\/\/doi.org\/10.1111\/dom.12252 (2014).","DOI":"10.1111\/dom.12252"},{"key":"83974_CR16","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/hep.30113","volume":"68","author":"ST Hui","year":"2018","unstructured":"Hui, S. T. et al. The genetic architecture of diet-induced hepatic fibrosis in mice. Hepatology 68, 2182\u20132196. https:\/\/doi.org\/10.1002\/hep.30113 (2018).","journal-title":"Hepatology"},{"key":"83974_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/labinvest.2014.11","volume":"94","author":"W Liang","year":"2014","unstructured":"Liang, W. et al. Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1beta-induced chronic inflammation. Lab Invest 94, 491\u2013502. https:\/\/doi.org\/10.1038\/labinvest.2014.11 (2014).","journal-title":"Lab Invest"},{"key":"83974_CR18","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1111\/bph.13315","volume":"172","author":"W Liang","year":"2015","unstructured":"Liang, W. et al. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. Br J Pharmacol 172, 5293\u20135305. https:\/\/doi.org\/10.1111\/bph.13315 (2015).","journal-title":"Br J Pharmacol"},{"key":"83974_CR19","doi-asserted-by":"publisher","unstructured":"van den Hoek, A. M. et al. icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity, and fibrosis in mice. Hepatol Commun 4, 193\u2013207, https:\/\/doi.org\/10.1002\/hep4.1453 (2020).","DOI":"10.1002\/hep4.1453"},{"key":"83974_CR20","doi-asserted-by":"publisher","unstructured":"Bijland, S. et al. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. J Biol Chem 285, 25168\u201325175. https:\/\/doi.org\/10.1074\/jbc.M110.123992 (2010).","DOI":"10.1074\/jbc.M110.123992"},{"key":"83974_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey, F. E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 377, 211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1612790 (2017).","journal-title":"N Engl J Med"},{"key":"83974_CR22","doi-asserted-by":"publisher","unstructured":"Kuhnast, S. et al. Niacin reduces atherosclerosis development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. PLoS One 8, e66467, https:\/\/doi.org\/10.1371\/journal.pone.0066467 (2013).","DOI":"10.1371\/journal.pone.0066467"},{"key":"83974_CR23","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S Kuhnast","year":"2014","unstructured":"Kuhnast, S. et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res 55, 2103\u20132112. https:\/\/doi.org\/10.1194\/jlr.M051326 (2014).","journal-title":"J Lipid Res"},{"key":"83974_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/eurheartj\/ehu319","volume":"36","author":"S Kuhnast","year":"2015","unstructured":"Kuhnast, S. et al. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J 36, 39\u201348. https:\/\/doi.org\/10.1093\/eurheartj\/ehu319 (2015).","journal-title":"Eur Heart J"},{"key":"83974_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14643","author":"G Stokman","year":"2020","unstructured":"Stokman, G. et al. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver Int https:\/\/doi.org\/10.1111\/liv.14643 (2020).","journal-title":"Liver Int"},{"key":"83974_CR26","doi-asserted-by":"publisher","unstructured":"van der Hoorn, J. W. et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 28, 2016\u20132022, https:\/\/doi.org\/10.1161\/ATVBAHA.108.171363 (2008).","DOI":"10.1161\/ATVBAHA.108.171363"},{"key":"83974_CR27","doi-asserted-by":"publisher","unstructured":"van der Hoogt, C. C. et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 48, 1763\u20131771, https:\/\/doi.org\/10.1194\/jlr.M700108-JLR200 (2007).","DOI":"10.1194\/jlr.M700108-JLR200"},{"key":"83974_CR28","doi-asserted-by":"publisher","unstructured":"Jiang, X. C., Agellon, L. B., Walsh, A., Breslow, J. L. & Tall, A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 90, 1290\u20131295, https:\/\/doi.org\/10.1172\/JCI115993 (1992).","DOI":"10.1172\/JCI115993"},{"key":"83974_CR29","doi-asserted-by":"crossref","unstructured":"van den Maagdenberg, A. M. et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 268, 10540\u201310545 (1993).","DOI":"10.1016\/S0021-9258(18)82232-3"},{"key":"83974_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejphar.2015.03.089","volume":"763","author":"S Kuhnast","year":"2015","unstructured":"Kuhnast, S., Fiocco, M., van der Hoorn, J. W., Princen, H. M. & Jukema, J. W. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C\/LDL-C-lowering versus HDL-C-raising: a systematic review and meta-analysis of relevant preclinical studies and clinical trials. Eur J Pharmacol 763, 48\u201363. https:\/\/doi.org\/10.1016\/j.ejphar.2015.03.089 (2015).","journal-title":"Eur J Pharmacol"},{"key":"83974_CR31","doi-asserted-by":"publisher","unstructured":"Princen, H. M. G., Pouwer, M. G. & Pieterman, E. J. Comment on \"Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice\" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46\u201354. Toxicol Rep. 3, 306\u2013309, https:\/\/doi.org\/10.1016\/j.toxrep.2016.02.002 (2016).","DOI":"10.1016\/j.toxrep.2016.02.002"},{"key":"83974_CR32","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1161\/01.atv.17.11.3064","volume":"17","author":"SM Post","year":"1997","unstructured":"Post, S. M., de Wit, E. C. & Princen, H. M. Cafestol, the cholesterol-raising factor in boiled coffee, suppresses bile acid synthesis by downregulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase in rat hepatocytes. Arterioscler Thromb Vasc Biol 17, 3064\u20133070. https:\/\/doi.org\/10.1161\/01.atv.17.11.3064 (1997).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"83974_CR33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321. https:\/\/doi.org\/10.1002\/hep.20701 (2005).","journal-title":"Hepatology"},{"key":"83974_CR34","doi-asserted-by":"publisher","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","volume":"9","author":"W Liang","year":"2014","unstructured":"Liang, W. et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS ONE 9, e115922. https:\/\/doi.org\/10.1371\/journal.pone.0115922 (2014).","journal-title":"PLoS ONE"},{"key":"83974_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos, D. G., Vos, M. B. & Brunt, E. M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5, 145\u2013171. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102132 (2010).","journal-title":"Annu Rev Pathol"},{"key":"83974_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1755-8794-7-35","volume":"7","author":"L Verschuren","year":"2014","unstructured":"Verschuren, L. et al. A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. BMC Med Genomics 7, 35. https:\/\/doi.org\/10.1186\/1755-8794-7-35 (2014).","journal-title":"BMC Med Genomics"},{"key":"83974_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol"},{"key":"83974_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","volume":"18","author":"M Ahrens","year":"2013","unstructured":"Ahrens, M. et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18, 296\u2013302. https:\/\/doi.org\/10.1016\/j.cmet.2013.07.004 (2013).","journal-title":"Cell Metab"},{"key":"83974_CR39","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/hep.27695","volume":"61","author":"BM Arendt","year":"2015","unstructured":"Arendt, B. M. et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61, 1565\u20131578. https:\/\/doi.org\/10.1002\/hep.27695 (2015).","journal-title":"Hepatology"},{"key":"83974_CR40","doi-asserted-by":"publisher","first-page":"15538","DOI":"10.1073\/pnas.1412759111","volume":"111","author":"S Horvath","year":"2014","unstructured":"Horvath, S. et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci USA 111, 15538\u201315543. https:\/\/doi.org\/10.1073\/pnas.1412759111 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"83974_CR41","doi-asserted-by":"publisher","first-page":"e46584","DOI":"10.1371\/journal.pone.0046584","volume":"7","author":"J Starmann","year":"2012","unstructured":"Starmann, J. et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS ONE 7, e46584. https:\/\/doi.org\/10.1371\/journal.pone.0046584 (2012).","journal-title":"PLoS ONE"},{"key":"83974_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/hep.26661","volume":"59","author":"CA Moylan","year":"2014","unstructured":"Moylan, C. A. et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59, 471\u2013482. https:\/\/doi.org\/10.1002\/hep.26661 (2014).","journal-title":"Hepatology"},{"key":"83974_CR43","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1161\/01.ATV.0000238348.05028.14","volume":"26","author":"T Kooistra","year":"2006","unstructured":"Kooistra, T. et al. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 26, 2322\u20132330. https:\/\/doi.org\/10.1161\/01.ATV.0000238348.05028.14 (2006).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"83974_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","volume":"116","author":"JI Lee","year":"2021","unstructured":"Lee, J. I., Lee, H. W., Lee, K. S., Lee, H. S. & Park, J. Y. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am J Gastroenterol 116, 116\u2013124. https:\/\/doi.org\/10.14309\/ajg.0000000000000845 (2021).","journal-title":"Am J Gastroenterol"},{"key":"83974_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","volume":"284","author":"F Nascimbeni","year":"2019","unstructured":"Nascimbeni, F. et al. Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes. Atherosclerosis 284, 66\u201374. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.028 (2019).","journal-title":"Atherosclerosis"},{"key":"83974_CR46","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2337\/dc11-0093","volume":"34","author":"B Cariou","year":"2011","unstructured":"Cariou, B., Zair, Y., Staels, B. & Bruckert, E. Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 34, 2008\u20132014. https:\/\/doi.org\/10.2337\/dc11-0093 (2011).","journal-title":"Diabetes Care"},{"key":"83974_CR47","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.2337\/dc12-2012","volume":"36","author":"B Cariou","year":"2013","unstructured":"Cariou, B. et al. Dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36, 2923\u20132930. https:\/\/doi.org\/10.2337\/dc12-2012 (2013).","journal-title":"Diabetes Care"},{"key":"83974_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS Tolbol","year":"2018","unstructured":"Tolbol, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 24, 179\u2013194. https:\/\/doi.org\/10.3748\/wjg.v24.i2.179 (2018).","journal-title":"World J Gastroenterol"},{"key":"83974_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7, 27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703 (2016).","journal-title":"J Basic Clin Pharm"},{"key":"83974_CR50","doi-asserted-by":"publisher","unstructured":"Abe, N. et al. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients. Biol Open 8, https:\/\/doi.org\/10.1242\/bio.041251 (2019).","DOI":"10.1242\/bio.041251"},{"key":"83974_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0378-4274(98)00042-3","volume":"98","author":"AD Edgar","year":"1998","unstructured":"Edgar, A. D. et al. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett 98, 13\u201323. https:\/\/doi.org\/10.1016\/s0378-4274(98)00042-3 (1998).","journal-title":"Toxicol Lett"},{"key":"83974_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tox.2007.09.030","volume":"246","author":"FJ Gonzalez","year":"2008","unstructured":"Gonzalez, F. J. & Shah, Y. M. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246, 2\u20138. https:\/\/doi.org\/10.1016\/j.tox.2007.09.030 (2008).","journal-title":"Toxicology"},{"key":"83974_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mce.2014.12.027","volume":"402","author":"TL Rachid","year":"2015","unstructured":"Rachid, T. L. et al. Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice. Mol Cell Endocrinol 402, 86\u201394. https:\/\/doi.org\/10.1016\/j.mce.2014.12.027 (2015).","journal-title":"Mol Cell Endocrinol"},{"key":"83974_CR54","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2337\/diab.46.8.1319","volume":"46","author":"D Auboeuf","year":"1997","unstructured":"Auboeuf, D. et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319\u20131327. https:\/\/doi.org\/10.2337\/diab.46.8.1319 (1997).","journal-title":"Diabetes"},{"key":"83974_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","volume":"136","author":"S Kersten","year":"2017","unstructured":"Kersten, S. & Stienstra, R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie 136, 75\u201384. https:\/\/doi.org\/10.1016\/j.biochi.2016.12.019 (2017).","journal-title":"Biochimie"},{"key":"83974_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1124\/mol.53.1.14","volume":"53","author":"CN Palmer","year":"1998","unstructured":"Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L. & Johnson, E. F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53, 14\u201322 (1998).","journal-title":"Mol Pharmacol"},{"key":"83974_CR57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1749-6632.1996.tb18620.x","volume":"804","author":"JD Tugwood","year":"1996","unstructured":"Tugwood, J. D., Aldridge, T. C., Lambe, K. G., Macdonald, N. & Woodyatt, N. J. Peroxisome proliferator-activated receptors: structures and function. Ann N Y Acad Sci 804, 252\u2013265. https:\/\/doi.org\/10.1111\/j.1749-6632.1996.tb18620.x (1996).","journal-title":"Ann N Y Acad Sci"},{"key":"83974_CR58","doi-asserted-by":"publisher","unstructured":"de la Rosa Rodriguez, M. A. et al. The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice. BMC Genomics 19, 443, https:\/\/doi.org\/10.1186\/s12864-018-4834-3 (2018).","DOI":"10.1186\/s12864-018-4834-3"},{"key":"83974_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","volume":"101","author":"R Kleemann","year":"2003","unstructured":"Kleemann, R. et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C\/EBP-beta complex formation. Blood 101, 545\u2013551. https:\/\/doi.org\/10.1182\/blood-2002-06-1762 (2003).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83974-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:31:59Z","timestamp":1670023919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83974-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83974"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83974-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5050"}}